Longitudinal analysis of safety and medication adherence of patients in the Fingolimod patient support program: a real-world observational study

Abstract The Fingolimod Patient Support Program (F-PSP) is an interprofessional specialty pharmacy service designed to ensure responsible use of fingolimod by promoting patient safety and medication adherence. This study aims to evaluate the safety and medication adherence of patients who joined the...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Aline Bourdin, Marie Paule Schneider, Isabella Locatelli, Myriam Schluep, Olivier Bugnon, Jérôme Berger
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/ed115b9beb674920aeb31c9096d0223c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ed115b9beb674920aeb31c9096d0223c
record_format	dspace
spelling	oai:doaj.org-article:ed115b9beb674920aeb31c9096d0223c2021-12-02T10:54:30ZLongitudinal analysis of safety and medication adherence of patients in the Fingolimod patient support program: a real-world observational study10.1038/s41598-021-83220-12045-2322https://doaj.org/article/ed115b9beb674920aeb31c9096d0223c2021-02-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-83220-1https://doaj.org/toc/2045-2322Abstract The Fingolimod Patient Support Program (F-PSP) is an interprofessional specialty pharmacy service designed to ensure responsible use of fingolimod by promoting patient safety and medication adherence. This study aims to evaluate the safety and medication adherence of patients who joined the F-PSP between 2013 and 2016. Sociodemographic and medical characteristics, patient safety data (patient-reported symptoms, discontinuations due to adverse events (AEs), repeated first-dose monitoring), and medication adherence (implementation, persistence, reasons for discontinuation, influence of covariates, barriers and facilitators) were described. Sixty-seven patients joined the F-PSP. Patients reported a high frequency of symptoms. Due to AEs, 7 patients discontinued fingolimod, 3 took therapeutic breaks, and 1 reduced the regimen temporarily. Three patients repeated the first-dose monitoring. Patients had a high medication adherence over the 18-month analysis period: implementation decreased from 98.8 to 93.7%, and fingolimod persistence was 83.2% at 18 months. The patients’ level of education, professional situation, and living with child(ren) influenced implementation. Patients reported more facilitators of medication adherence than barriers. The F-PSP seems valuable for supporting individual patients (ensuring responsible use of fingolimod and inviting patients for shared-decision making) and public health (indirectly gathering real-world evidence).Aline BourdinMarie Paule SchneiderIsabella LocatelliMyriam SchluepOlivier BugnonJérôme BergerNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Aline Bourdin Marie Paule Schneider Isabella Locatelli Myriam Schluep Olivier Bugnon Jérôme Berger Longitudinal analysis of safety and medication adherence of patients in the Fingolimod patient support program: a real-world observational study
description	Abstract The Fingolimod Patient Support Program (F-PSP) is an interprofessional specialty pharmacy service designed to ensure responsible use of fingolimod by promoting patient safety and medication adherence. This study aims to evaluate the safety and medication adherence of patients who joined the F-PSP between 2013 and 2016. Sociodemographic and medical characteristics, patient safety data (patient-reported symptoms, discontinuations due to adverse events (AEs), repeated first-dose monitoring), and medication adherence (implementation, persistence, reasons for discontinuation, influence of covariates, barriers and facilitators) were described. Sixty-seven patients joined the F-PSP. Patients reported a high frequency of symptoms. Due to AEs, 7 patients discontinued fingolimod, 3 took therapeutic breaks, and 1 reduced the regimen temporarily. Three patients repeated the first-dose monitoring. Patients had a high medication adherence over the 18-month analysis period: implementation decreased from 98.8 to 93.7%, and fingolimod persistence was 83.2% at 18 months. The patients’ level of education, professional situation, and living with child(ren) influenced implementation. Patients reported more facilitators of medication adherence than barriers. The F-PSP seems valuable for supporting individual patients (ensuring responsible use of fingolimod and inviting patients for shared-decision making) and public health (indirectly gathering real-world evidence).
format	article
author	Aline Bourdin Marie Paule Schneider Isabella Locatelli Myriam Schluep Olivier Bugnon Jérôme Berger
author_facet	Aline Bourdin Marie Paule Schneider Isabella Locatelli Myriam Schluep Olivier Bugnon Jérôme Berger
author_sort	Aline Bourdin
title	Longitudinal analysis of safety and medication adherence of patients in the Fingolimod patient support program: a real-world observational study
title_short	Longitudinal analysis of safety and medication adherence of patients in the Fingolimod patient support program: a real-world observational study
title_full	Longitudinal analysis of safety and medication adherence of patients in the Fingolimod patient support program: a real-world observational study
title_fullStr	Longitudinal analysis of safety and medication adherence of patients in the Fingolimod patient support program: a real-world observational study
title_full_unstemmed	Longitudinal analysis of safety and medication adherence of patients in the Fingolimod patient support program: a real-world observational study
title_sort	longitudinal analysis of safety and medication adherence of patients in the fingolimod patient support program: a real-world observational study
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/ed115b9beb674920aeb31c9096d0223c
work_keys_str_mv	AT alinebourdin longitudinalanalysisofsafetyandmedicationadherenceofpatientsinthefingolimodpatientsupportprogramarealworldobservationalstudy AT mariepauleschneider longitudinalanalysisofsafetyandmedicationadherenceofpatientsinthefingolimodpatientsupportprogramarealworldobservationalstudy AT isabellalocatelli longitudinalanalysisofsafetyandmedicationadherenceofpatientsinthefingolimodpatientsupportprogramarealworldobservationalstudy AT myriamschluep longitudinalanalysisofsafetyandmedicationadherenceofpatientsinthefingolimodpatientsupportprogramarealworldobservationalstudy AT olivierbugnon longitudinalanalysisofsafetyandmedicationadherenceofpatientsinthefingolimodpatientsupportprogramarealworldobservationalstudy AT jeromeberger longitudinalanalysisofsafetyandmedicationadherenceofpatientsinthefingolimodpatientsupportprogramarealworldobservationalstudy
_version_	1718396503687430144

Longitudinal analysis of safety and medication adherence of patients in the Fingolimod patient support program: a real-world observational study

Ejemplares similares